GT103

DRUG2 trials

Sponsors

Edward Patz, Jeffrey Clarke

Conditions

Metastatic NSCLCNon Small Cell Lung CancerNon-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer

Phase 1

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

CompletedNCT04314089

Edward PatzNon-small Cell Lung Cancer

Start: 2020-06-09End: 2024-12-30Updated: 2025-06-17

Phase 2

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

TerminatedNCT05617313

Jeffrey ClarkeMetastatic NSCLC, Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer

Start: 2023-02-17End: 2025-06-26Updated: 2025-07-30

Related Papers

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

2025-01-0210 citations

Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.

Journal of Clinical Oncology2024-06-011 citations

Abstract 2915: Targeting complement factor H renders STK11-mutant lung adenocarcinoma sensitive to anti-PD-1 therapy in mice

Cancer Research2024-03-22

Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2023-06-013 citations

699 Interim results from a phase IB, first-in-human study of a novel complement factor h inhibitor (GT103) in patients with refractory non-small cell lung cancer (NSCLC)

Regular and Young Investigator Award Abstracts2022-11-011 citations